Arcus Biosciences Inc.

8.16
-0.33 (-3.89%)
At close: Mar 28, 2025, 3:59 PM
8.21
0.49%
After-hours: Mar 28, 2025, 08:00 PM EDT

Company Description

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States.

Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.

The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease.

It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer.

The company was incorporated in 2015 and is headquartered in Hayward, California.

Arcus Biosciences Inc.
Arcus Biosciences Inc. logo
Country United States
IPO Date Mar 15, 2018
Industry Biotechnology
Sector Healthcare
Employees 627
CEO Dr. Terry J. Rosen Ph.D.

Contact Details

Address:
3928 Point Eden Way
Hayward, California
United States
Website https://www.arcusbio.com

Stock Details

Ticker Symbol RCUS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001724521
CUSIP Number 03969F109
ISIN Number US03969F1093
Employer ID 47-3898435
SIC Code 2834

Key Executives

Name Position
Dr. Terry J. Rosen Ph.D. Co-Founder, Chairman & Chief Executive Officer
Jennifer A. Jarrett M.B.A. Chief Operating Officer
Robert C. Goeltz II Principal Financial Officer & Chief Financial Officer
Alexander Azoy CPA Vice President of Finance & Principal Accounting Officer
Carolyn C. Tang J.D. General Counsel & Corporate Secretary
Dr. Jonathan Yingling Ph.D. Chief Scientific Officer
Dr. Juan Carlos Jaen Ph.D. Co- Founder & President
Dr. K. Christopher Garcia Ph.D. Co-Founder & Member of Scientific Advisory Board
Holli Kolkey Vice President of Corporate Communications
Pia Eaves Vice President of Investor Relations & Strategy

Latest SEC Filings

Date Type Title
Mar 05, 2025 SCHEDULE 13D/A [Amend] Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 25, 2025 S-8 Filing
Feb 25, 2025 10-K Annual Report
Feb 25, 2025 8-K Current Report
Feb 20, 2025 SCHEDULE 13D/A [Amend] Filing
Feb 20, 2025 4 Filing
Feb 19, 2025 8-K Current Report
Feb 18, 2025 424B5 Filing